Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP-PEG-RC48-R848
- Development stage
- Preclinical
- Lead developer
- Shantou University
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**BP-PEG-RC48-R848** is an experimental HER2-targeted black-phosphorus nanocomposite developed for photothermal-immunotherapy of HER2-positive breast cancer. It incorporates PEGylated two-dimensional black phosphorus as a near-infrared photothermal nanocarrier, the HER2-directed antibody-drug conjugate disitamab vedotin, and resiquimod, a Toll-like receptor 7 and Toll-like receptor 8 agonist. Disitamab vedotin directs the construct to HER2-expressing tumor cells and delivers the microtubule-disrupting payload monomethyl auristatin E, while resiquimod promotes dendritic-cell maturation and pro-inflammatory immune activation. In preclinical tumor models, near-infrared irradiation of the tumor-localized nanocomposite produced photothermal tumor ablation and enhanced antitumor immune responses.
- Other names
- BP-PEG-RC48-R848BP-PEG-RC-48-R848BP-PEG-RC 48-R848
02
Targets
TUBB (Tubulin (alpha and beta subunits))TLR7 (Toll-like receptor 7)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on BP-PEG-RC48-R848.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BP-PEG-RC48-R848.